H.C. Wainwright raised the firm’s price target on Travere Therapeutics to $23 from $20 and keeps a Buy rating on the shares after the granted full approval to Filspari. The firm says the approval brings validation and a broader label. It sees “several meaningful benefits” from the FDA’s action for the Filspari commercial business and Travere overall.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics trading resumes
- Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
- Travere Therapeutics’ Filspari in kidney function granted full approval by FDA
- Travere Therapeutics trading halted, news pending
- Evercore says Filspari inclusion in new guidelines should give Travere boost